Drugs / VXA-CoV2-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04563702 | Sep 2020 → Oct 2021 | COVID-19 | Vaxart | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-05-03 | Vaxart | Results New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses vaxart.com ↗
Data obtained from the Phase I study were compared to data from volunteers subsequently vaccinated with the Moderna or Pfizer mRNA vaccine distributed under emergency use authorizations (EUAs) and suggest that the same may be true against coronavirus. |
| 2021-04-22 | Vaxart | Results Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans vaxart.com ↗
The study reached primary and secondary endpoints of safety and immunogenicity, respectively. |
| 2021-02-03 | Vaxart | Results Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate vaxart.com ↗
VXA-CoV2-1 induced potent CD8+ T-cell responses |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXA-CoV2-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04563702 ↗ |
| Modality | Vaccine | “non replicating Ad5 adjuvanted oral tableted vaccine” NCT04563702 ↗ |
| Route | Oral | “administered Orally” NCT04563702 ↗ |